NICE draft guidance provides Cancer Drugs Fund first in Europe access to new treatment option for advanced breast cancer

Wednesday 21 Apr 2021 @ 11:15
National Institute for Health and Clinical Excellence (NICE)

NICE yesterday (20 April 2021) published draft guidance recommending trastuzumab deruxtecan for use in the Cancer Drugs Fund (CDF) for treating a type of breast cancer called HER2 positive breast cancer which can’t be surgically removed or which has spread to other parts of the body.

Channel website: https://www.nice.org.uk/

Original article link: https://www.nice.org.uk/news/article/nice-draft-guidance-provides-cancer-drugs-fund-first-in-europe-access-to-new-treatment-option-for-advanced-breast-cancer

Share this article

Latest News from
National Institute for Health and Clinical Excellence (NICE)

170,000 people in England to have further treatment choice for preventing migraine attacks.

11/04/2024 16:05:00

In final draft guidance published today NICE has recommended atogepant, the first of a new type of oral treatment option for preventing both chronic and episodic migraines, opening the way for up to 170,000 people to choose it on the NHS in England

Children and young adults to benefit after NICE recommends personalised immunotherapy to treat blood cancer be made routinely available on the NHS

11/04/2024 15:05:00

Innovative CAR-T therapy recommended to treat an aggressive form of leukaemia

NICE launches second consultation on genetic testing to guide treatment after a stroke

03/04/2024 14:15:00

People could be offered a genetic test in the immediate period after having a stroke to help identify the most suitable treatment to reduce their risk of further strokes.

25,000 people to benefit after NICE recommends new ulcerative colitis treatment

12/03/2024 15:05:00

New one-a-day pill recommended on the same day the treatment was granted a licence by the MHRA

NICE publishes final draft guidance on Enhertu after commercial discussions conclude without a price to make it a cost-effective use of NHS resources.

06/03/2024 14:05:00

NICE has published final draft guidance that does not recommend Enhertu (also called trastuzumab deruxtecan and made by Daiichi Sankyo) for treating advanced HER2-low breast cancer in adults.

WIREDGOV